SOPHiA GENETICS Expands Global Liquid Biopsy Testing Collaboration with AstraZeneca

SOPHiA GENETICS and AstraZeneca: Transforming Liquid Biopsy Testing

In a groundbreaking move for oncology diagnostics, SOPHiA GENETICS, the renowned cloud-native healthcare technology company, has announced an expansion of its collaboration with AstraZeneca. This development aims to enhance the global deployment of MSK-ACCESS® combined with the innovative SOPHiA DDM™ technology. With this new phase set for 2025, the initiative will extend its reach to a total of 30 clinical institutions worldwide.

Originally established in October 2024, the collaboration focuses on MSK-ACCESS®, a liquid biopsy testing application designed to identify critical genomic alterations from a simple blood draw. This application employs advanced algorithms to scrutinize circulating tumor DNA (ctDNA), facilitating real-time cancer monitoring and treatment selection, especially when traditional tissue biopsies are either impractical or financially unfeasible.

The Evolution of Liquid Biopsy Testing

Liquid biopsy presents a significant advancement in oncology, as it overcomes several challenges associated with tissue biopsies. Not only is it less invasive, but it also significantly reduces costs and turnaround times associated with traditional procedures. This new partnership between SOPHiA GENETICS and AstraZeneca signifies a shared goal to democratize access to this pioneering technology, thereby affecting patient outcomes positively across the globe.

The announcement of this expanded collaboration aligns with SOPHiA GENETICS's recent presentation at the American Association for Cancer Research's Annual Meeting. The company revealed data showcasing the transferability and reliability of its decentralized MSK-ACCESS® solution, addressing a long-standing issue within the field — site-to-site discordance. Historically, this inconsistency has hindered the universal adoption of liquid biopsy testing, but new real-world data unambiguously demonstrated the ongoing accuracy and precision of the MSK-ACCESS® technology across various laboratory environments.

Demonstrating Impact through Data

Interim results from a multi-center study highlighted the analytical performance of the decentralized test, aligning closely with results from the prestigious Memorial Sloan Kettering Cancer Center in New York. These findings bolster the case for liquid biopsy testing as a complementary technique to solid tissue testing, offering an alternative that benefits both laboratories and patients alike.

Ross Muken, President of SOPHiA GENETICS, stated, "Our collaboration with AstraZeneca marks a significant leap toward global scalability of next-generation oncology diagnostics." This sentiment reflects the growing momentum within the liquid biopsy sector, emphasizing their concerted efforts to make these technologies more accessible and influential around the world.

The Future of Oncology Diagnostics

As SOPHiA GENETICS and AstraZeneca gear up for this expansion, the potential to reshape the landscape of oncology diagnostics is evident. By investing in the advancement of liquid biopsy testing, the two firms aim to further validate its clinical impact within diverse healthcare systems, thus fostering a deeper understanding of how these tests can enhance patient care overall.

Professionals and stakeholders are encouraged to learn more about this collaboration at the AACR Annual Meeting held in Chicago, Illinois, from April 25th–30th. SOPHiA GENETICS continues to position itself as a leader in data-driven medical solutions designed to empower healthcare providers globally.

For more information about SOPHiA GENETICS and its impactful initiatives, please visit SOPHiAGENETICS.COM, or follow them on LinkedIn to stay updated on their latest advancements and offerings.